

## Product datasheet for **TL300593**

### VAC14 Human shRNA Plasmid Kit (Locus ID 55697)

#### Product data:

Product Type:	shRNA Plasmids
Product Name:	VAC14 Human shRNA Plasmid Kit (Locus ID 55697)
Locus ID:	55697
Synonyms:	ArPIKfyve; TAX1BP2; TRX
Vector:	pGFP-C-shLenti (TR30023)
E. coli Selection:	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection:	Puromycin
Format:	Lentiviral plasmids
Components:	VAC14 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 55697). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq:	<a href="#">NM_018052</a> , <a href="#">NM_001351157</a> , <a href="#">NM_018052.1</a> , <a href="#">NM_018052.2</a> , <a href="#">NM_018052.3</a> , <a href="#">BC125108</a> , <a href="#">BC000536</a> , <a href="#">BC007214</a> , <a href="#">BC110072</a> , <a href="#">BC110852</a> , <a href="#">BC125109</a> , <a href="#">NM_018052.5</a>
UniProt ID:	<a href="#">Q08AM6</a>
Summary:	This gene encodes a scaffold protein that is a component of the PIKfyve protein kinase complex. This complex is responsible for the synthesis of phosphatidylinositol 3,5-bisphosphate, an important component of cellular membranes, from phosphatidylinositol 3-phosphate. Mice lacking a functional copy of this gene exhibit severe neurodegeneration. Mutations in the human gene have been identified in patients with a childhood onset progressive neurological disorder characterized by impaired movement, dystonia, and striatal abnormalities. [provided by RefSeq, May 2017]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .


[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).